Andrew Cheng - 08 Oct 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President and CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 08 Oct 2025
Net transactions value: +$32,110
Form type: 4
Filing time: 09 Oct 2025, 18:58:03 UTC
Previous filing: 12 Sep 2025
Next filing: 14 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cheng Andrew	President and CEO, Director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO	/s/ Jonathan Young, Attorney-in-Fact	09 Oct 2025	0001778307

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$32,110	+52,212	+11%	$0.6150	526,114	08 Oct 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-52,212	-100%	$0.000000	0	08 Oct 2025	Common Stock	52,212	$0.6150	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options are vested and currently exercisable.